Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• Group NM-ACChemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trialsJ Clin Oncol200826284617462518678835
   PubMed Web of Science ®Google Scholar
• ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol200018102095210310811675
   PubMed Web of Science ®Google Scholar
• FossellaFVDeVoreRKerrRNRandomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study GroupJ Clin Oncol200018122354236210856094
   PubMed Web of Science ®Google Scholar
• CarneyDNLung cancer – time to move on from chemotherapyN Engl J Med2002346212612811784881
   PubMed Web of Science ®Google Scholar
• QiWXWangQJiangYLOverall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published dataPLoS One201382e5563723409011
   PubMed Web of Science ®Google Scholar
• FolkmanJAnti-angiogenesis: new concept for therapy of solid tumorsAnn Surg197217534094165077799
   PubMed Web of Science ®Google Scholar
• PallisAGSyrigosKNTargeting tumor neovasculature in non-small-cell lung cancerCrit Rev Oncol Hematol201386213014223159217
   PubMed Web of Science ®Google Scholar
• LammersPEHornLTargeting angiogenesis in advanced non-small cell lung cancerJ Natl Compr Canc Netw201311101235124724142825
   PubMed Web of Science ®Google Scholar
• ReckampKLAntiangiogenic agents as second-line therapy for advanced non-small cell lung cancerCancer Lett2012321210110922306704
   PubMed Web of Science ®Google Scholar
• QiWXTangLNHeANShenZYaoYThe role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trialsLung2011189643744321986852
   PubMed Web of Science ®Google Scholar
• LauroSOnestiCERighiniRMarchettiPThe use of bevacizumab in non-small cell lung cancer: an updateAnticancer Res20143441537154524692680
   PubMed Web of Science ®Google Scholar
• SoriaJCMauguenAReckMMeta-analysis of bevacizumab in advanced NcgSystematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerAnn Oncol2013241203023180113
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• BelaniCPYamamotoNBondarenkoIMRandomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancerBMC Cancer20141429024766732
   PubMed Web of Science ®Google Scholar
• ReckMKaiserRMellemgaardAfor the L-LSGDocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639
   PubMed Web of Science ®Google Scholar
• ClarkeJMHurwitzHITargeted inhibition of VEGF receptor 2: an update on ramucirumabExpert Opin Biol Ther20131381187119623803182
   PubMed Web of Science ®Google Scholar
• LaurieSASolomonBJSeymourLRandomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29Eur J Cancer201450470671224360368
   PubMed Web of Science ®Google Scholar
• ScagliottiGVFelipEBesseBAn open-label, multicenter, randomized, phase ii study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancerJ Thorac Oncol20138121529153724389434
   PubMed Web of Science ®Google Scholar
• Van CutsemERiveraFBerrySFirst BEAT InvestigatorsSafety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnn Oncol200920111842184719406901
   PubMed Web of Science ®Google Scholar
• MelnykOZimmermanMKimKJShumanMNeutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical modelJ Urol1999161396096310022734
   PubMed Web of Science ®Google Scholar
• MesianoSFerraraNJaffeRBRole of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralizationAm J Pathol19981534124912569777956
   PubMed Web of Science ®Google Scholar
• KlementGBaruchelSRakJContinuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJ Clin Invest20001058R15R2410772661
   PubMed Web of Science ®Google Scholar
• MancusoMRDavisRNorbergSMRapid vascular regrowth in tumors after reversal of VEGF inhibitionJ Clin Invest2006116102610262117016557
   PubMed Web of Science ®Google Scholar
• VosselerSMiranceaNBohlenPMuellerMMFusenigNEAngiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplantsCancer Res20056541294130515735015
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldDInvestigators MLSContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med20096e100009719621072
   PubMed Web of Science ®Google Scholar
• MoherDPhamBJonesADoes quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet199835291286096139746022
   PubMed Web of Science ®Google Scholar
• ZintzarasEIoannidisJPHeterogeneity testing in meta-analysis of genome searchesGenet Epidemiol200528212313715593093
   PubMed Web of Science ®Google Scholar
• VandenbrouckeJPBias in meta-analysis detected by a simple, graphical test. Experts’ views are still neededBMJ19983167129469470 author reply 470–4619492686
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
   PubMed Web of Science ®Google Scholar
• ScagliottiGVKrzakowskiMSzczesnaASunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trialJ Clin Oncol201230172070207822564989
   PubMed Web of Science ®Google Scholar
• NataleRBThongprasertSGrecoFAPhase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancerJ Clin Oncol20112981059106621282542
   PubMed Web of Science ®Google Scholar
• de BoerRHArrietaOYangCHVandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trialJ Clin Oncol20112981067107421282537
   PubMed Web of Science ®Google Scholar
• HerbstRSSunYEberhardtWEVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialLancet Oncol201011761962620570559
   PubMed Web of Science ®Google Scholar
• SterneJAGavaghanDEggerMPublication and related bias in meta-analysis: power of statistical tests and prevalence in the literatureJ Clin Epidemiol200053111119112911106885
   PubMed Web of Science ®Google Scholar
• MellorHRCallaghanRResistance to chemotherapy in cancer: a complex and integrated cellular responsePharmacology200881427530018259091
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol201230283499350622949147
   PubMed Web of Science ®Google Scholar